Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: GlycoMimetics Incorporated Clear all
Terminated Phase 3 Interventional

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

NCT03616470
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Uproleselan, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

NCT02703051
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GMI-1271, Filgrastim, Placebo Injection, Placebo Infusion
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
19 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

NCT01119833
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions
GMI-1070, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
12 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

NCT02271113
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GMI-1271, Placebo, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

NCT01941511
View directory record Official record
Conditions
Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

NCT02168595
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
GMI-1271, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
19 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

NCT02931214
View directory record Official record
Conditions
Healthy
Interventions
GMI-1359, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
19 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 3 Interventional

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

NCT02433158
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, Pain Crisis, Vaso-occlusive Crisis
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
6 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
85
States / cities
Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

NCT02306291
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
GMI-1271, Mitoxantrone, Etoposide, Cytarabine, Idarubicin
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

NCT00911495
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GMI-1070
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Oakland, California • Sacramento, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

NCT02813798
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 1 Interventional

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

NCT05569512
View directory record Official record
Conditions
Acute Myeloid Leukemia, Pediatric Cancer
Interventions
Uproleselan, Fludarabine, Clofarabine, Busulfan
Drug
Lead sponsor
Malika Kapadia
Other
Eligibility
12 Months to 39 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 1 Interventional

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

NCT04964505
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Uproleselan, Venetoclax
Drug
Lead sponsor
Brian Jonas
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

NCT05057221
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Uproleselan
Drug
Lead sponsor
Lena Napolitano, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 1 Interventional

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

NCT04197999
View directory record Official record
Conditions
HR+ Metastatic Breast Cancer, Breast Cancer, Breast Cancer Metastatic
Interventions
GMI-1359
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

NCT02998099
View directory record Official record
Conditions
Healthy
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

NCT02744833
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
GMI-1271, Enoxaparin Sodium (Lovenox®)
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT02871570
View directory record Official record
Conditions
Moderate Hepatic Impairment, Normal Hepatic Function
Interventions
Rivipansel
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

NCT02187003
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Rivipansel, Placebo
Drug · Other
Lead sponsor
Biossil Inc.
Industry
Eligibility
6 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
126
States / cities
Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 5, 2026, 6:57 AM EDT